Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03783078 · OUTCOME

Overall Survival (OS)

Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913) · Source last updated 2025-05-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
Up to ~58 months

What was measured

OS was defined as the time from the first dose of study treatment until death from any cause.

Analysis population: The analysis population consisted of all allocated participants who received at least 1 dose of study treatment.

Groups in this outcome

Pembrolizumab 200 mg

Adult participants received pembrolizumab (MK-3475) 200 mg or pediatric participants received 2 mg/kg (up to 200 mg) on Day 1 Q3W IV for up to 35 administrations (approximately 2 years).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Pembrolizumab 200 mg55

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Pembrolizumab 200 mg24.3Not reported12.4NANA = Upper limit not reached at time of data cut-off due to insufficient number of participants with an event
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        NA = Upper limit not reached at time of data cut-off due to insufficient number of participants with an event
        group Id
        OG000
        lower Limit
        12.4
        upper Limit
        NA
        value
        24.3
denoms
  1. counts
    1. group Id
      OG000
      value
      55
    units
    Participants
description
OS was defined as the time from the first dose of study treatment until death from any cause.
dispersion Type
95% Confidence Interval
groups
  1. description
    Adult participants received pembrolizumab (MK-3475) 200 mg or pediatric participants received 2 mg/kg (up to 200 mg) on Day 1 Q3W IV for up to 35 administrations (approximately 2 years).
    id
    OG000
    title
    Pembrolizumab 200 mg
param Type
MEDIAN
population Description
The analysis population consisted of all allocated participants who received at least 1 dose of study treatment.
reporting Status
POSTED
time Frame
Up to ~58 months
title
Overall Survival (OS)
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice